<h2>最新的半年业绩对股东意味着什么</h2>
<p>Thomson Medical Group (SGX:A50) 刚刚发布了半年业绩，显示销售额为 2.1308 亿新元，而去年同期为 1.9906 亿新元，同时净亏损缩小至 1025 万新元。</p>
<p>来自持续经营的基本和稀释每股亏损为 0.00039 新元，而之前为 0.00049 新元。这让你了解该企业目前每股消耗的资本。</p>
<p>查看我们对 Thomson Medical Group 的最新分析。</p>
<p>在每股价格为 0.06 新元的情况下，Thomson Medical Group 在过去三个月的股价回报为 3.45%，而一年总股东回报为 30.43%，这表明随着亏损缩小和收入数据的变化，市场情绪正在改善。</p>
<p>如果这些结果让你重新评估医疗保健领域的机会，现在可能是通过我们精心挑选的 106 只医疗保健 AI 股票列表来扫描更广泛的医疗名称的好时机。</p>
<p>在每股价格为 0.06 新元、收入为 2.1308 亿新元且集团仍在报告净亏损的情况下，关键问题是当前价格是否反映了折扣，或者市场是否已经在定价改善的条件。</p>
<h2>偏好的市销率为 3.4 倍：是否合理？</h2>
<p>根据我们的数据，Thomson Medical Group 的市销率为 3.4 倍，相较于亚洲医疗行业及其最接近的同行而言显得昂贵。</p>
<p>市销率比较公司的市场价值与其收入。在 3.4 倍的情况下，投资者为 Thomson Medical Group 每产生 1 新元的年销售额支付 3.40 新元的股权价值。</p>
<p>这一水平高于亚洲医疗行业平均市销率 1.5 倍，也高于同行平均的 2.1 倍。这表明市场对 Thomson Medical Group 每一美元收入的估值高于许多竞争对手。然而，这一 3.4 倍的水平接近我们估算的合理市销率 3.6 倍，因此当前的比率距离市场在情绪或预期变化时可能合理移动的水平并不远。</p>
<p>探索 Thomson Medical Group 的 SWS 合理比率</p>
<p><strong>结果：市销率为 3.4 倍（被高估）</strong></p>
<p>然而，仍然存在明显的风险，包括持续的净亏损为 4492.1 万新元以及疲弱的多年股东回报，这可能会对今天更高的市销率标签构成挑战。</p>
<p>了解 Thomson Medical Group 叙述中的关键风险。</p>
<h2>价值的另一种视角：DCF 模型的看法</h2>
<p>虽然 3.4 倍的市销率在医疗同行中显得昂贵，但我们的 DCF 模型指向了不同的方向。它表明每股合理价值为 0.11 新元，而当前为 0.06 新元，这表明 Thomson Medical Group 的交易价格存在较大折扣。你更信任哪个信号？</p>
<p>了解 SWS DCF 模型如何得出其合理价值。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e690d03f-7cdf-477b-86cf-107b2708eedc/chart/dcf?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e690d03f-7cdf-477b-86cf-107b2708eedc/chart/dcf"/></p>
<p>截至 2026 年 2 月的 A50 折现现金流</p>
<p>Simply Wall St 每天对全球每只股票进行折现现金流（DCF）分析（例如查看 Thomson Medical Group）。我们展示了完整的计算过程。你可以在你的观察列表或投资组合中跟踪结果，并在变化时收到提醒，或者使用我们的股票筛选器发现 221 只高质量的被低估股票。如果你保存了筛选器，我们甚至会在新公司匹配时提醒你——这样你就不会错过潜在机会。</p>
<h2>下一步</h2>
<p>如果这些信号的组合让你感到有些矛盾，那是一个健康的开始。值得迅速行动，以便将自己的观点与 2 个关键回报和 1 个重要警告信号背后的数字和背景进行对比。</p>
<h2>寻找更多投资想法？</h2>
<p>如果 Thomson Medical Group 让你更加关注，不要止步于此。利用这一势头比较其他机会，并对你的投资组合决策进行压力测试。</p>
<ul>
<li>通过扫描我们 221 只高质量被低估股票的列表，寻找潜在的价值候选者，这些股票结合了稳健的基本面和更温和的定价。</li>
<li>通过检查我们的稳健资产负债表和基本面股票筛选器（369 个结果），增强你持有股票的质量，看看哪些公司用强健的财务支持他们的故事。</li>
<li>通过审查我们的 438 只股息堡垒，增加潜在的收入角度，以免错过提供更高收益且具有持久力的公司。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3>估值复杂，但我们在这里简化它。</h3>
<p>通过我们的详细分析，发现 Thomson Medical Group 是否可能被低估或高估，分析内容包括 <strong>合理价值估算、潜在风险、股息、内部交易及其财务状况。</strong></p>
<p>获取免费分析</p>

杰俐

<p>杰俐集团（SGX:A50）报告了半年的销售额为 2.1308 亿新元，较之前的 1.9906 亿新元有所增长，净亏损缩小至 1025 万新元。该公司的股价为 0.06 新元，反映出三个月内回报率为 3.45%，一年内回报率为 30.43%。当前的市销率（P/S）为 3.4 倍，高于行业平均水平，表明可能存在高估。然而，折现现金流分析显示每股公允价值为 0.11 新元，表明该股票可能被低估。建议投资者在评估机会时考虑这些混合信号</p>

<h2>What the latest half year results mean for shareholders</h2>
<div class="lb-trans"><h2>最新的半年业绩对股东意味着什么</h2>
</div><p>Thomson Medical Group (SGX:A50) has just posted half year numbers that show sales of S$213.08 million compared with S$199.06 million a year earlier, alongside a narrower net loss of S$10.25 million.</p>
<div class="lb-trans"><p>Thomson Medical Group (SGX:A50) 刚刚发布了半年业绩，显示销售额为 2.1308 亿新元，而去年同期为 1.9906 亿新元，同时净亏损缩小至 1025 万新元。</p>
</div><p>Basic and diluted loss per share from continuing operations came in at S$0.00039, versus S$0.00049 previously. This gives you a sense of how much capital the business is currently consuming per share.</p>
<div class="lb-trans"><p>来自持续经营的基本和稀释每股亏损为 0.00039 新元，而之前为 0.00049 新元。这让你了解该企业目前每股消耗的资本。</p>
</div><p>See our latest analysis for Thomson Medical Group.</p>
<div class="lb-trans"><p>查看我们对 Thomson Medical Group 的最新分析。</p>
</div><p>At a share price of S$0.06, Thomson Medical Group has seen a 3.45% 3 month share price return and a 30.43% 1 year total shareholder return, suggesting improving sentiment around the business as losses narrow and revenue figures shift.</p>
<div class="lb-trans"><p>在每股价格为 0.06 新元的情况下，Thomson Medical Group 在过去三个月的股价回报为 3.45%，而一年总股东回报为 30.43%，这表明随着亏损缩小和收入数据的变化，市场情绪正在改善。</p>
</div><p>If these results have you reassessing opportunities in healthcare, it could be a good moment to scan a wider field of medical names through our curated list of 106 healthcare AI stocks.</p>
<div class="lb-trans"><p>如果这些结果让你重新评估医疗保健领域的机会，现在可能是通过我们精心挑选的 106 只医疗保健 AI 股票列表来扫描更广泛的医疗名称的好时机。</p>
</div><p>With the shares at S$0.06, revenue at S$213.08 million and the group still reporting a net loss, the key question is whether the current price reflects a discount or whether the market is already pricing in an improvement in conditions.</p>
<div class="lb-trans"><p>在每股价格为 0.06 新元、收入为 2.1308 亿新元且集团仍在报告净亏损的情况下，关键问题是当前价格是否反映了折扣，或者市场是否已经在定价改善的条件。</p>
</div><h2>Preferred Price-to-Sales Multiple of 3.4x: Is it justified?</h2>
<div class="lb-trans"><h2>偏好的市销率为 3.4 倍：是否合理？</h2>
</div><p>On our data, Thomson Medical Group is trading on a P/S of 3.4x, which screens as expensive compared with both the Asian healthcare industry and its closest peers.</p>
<div class="lb-trans"><p>根据我们的数据，Thomson Medical Group 的市销率为 3.4 倍，相较于亚洲医疗行业及其最接近的同行而言显得昂贵。</p>
</div><p>The P/S ratio compares the company’s market value to its revenue. At 3.4x, investors are paying S$3.40 in equity value for every S$1 of annual sales Thomson Medical Group generates.</p>
<div class="lb-trans"><p>市销率比较公司的市场价值与其收入。在 3.4 倍的情况下，投资者为 Thomson Medical Group 每产生 1 新元的年销售额支付 3.40 新元的股权价值。</p>
</div><p>This is a richer tag than the Asian healthcare industry average P/S of 1.5x and also above the peer average of 2.1x. This suggests the market is attaching a higher value to each dollar of Thomson Medical Group’s revenue than it does for many competitors. However, this 3.4x level is close to our estimated fair P/S of 3.6x, so the current ratio is not far from a level the market could reasonably move towards if sentiment or expectations change.</p>
<div class="lb-trans"><p>这一水平高于亚洲医疗行业平均市销率 1.5 倍，也高于同行平均的 2.1 倍。这表明市场对 Thomson Medical Group 每一美元收入的估值高于许多竞争对手。然而，这一 3.4 倍的水平接近我们估算的合理市销率 3.6 倍，因此当前的比率距离市场在情绪或预期变化时可能合理移动的水平并不远。</p>
</div><p>Explore the SWS fair ratio for Thomson Medical Group</p>
<div class="lb-trans"><p>探索 Thomson Medical Group 的 SWS 合理比率</p>
</div><p><strong>Result: Price-to-sales of 3.4x (OVERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：市销率为 3.4 倍（被高估）</strong></p>
</div><p>However, there are still clear risks, including the ongoing net loss of S$44.921 million and weak multi year shareholder returns, which could challenge today’s richer P/S tag.</p>
<div class="lb-trans"><p>然而，仍然存在明显的风险，包括持续的净亏损为 4492.1 万新元以及疲弱的多年股东回报，这可能会对今天更高的市销率标签构成挑战。</p>
</div><p>Find out about the key risks to this Thomson Medical Group narrative.</p>
<div class="lb-trans"><p>了解 Thomson Medical Group 叙述中的关键风险。</p>
</div><h2>Another view on value: what the DCF is saying</h2>
<div class="lb-trans"><h2>价值的另一种视角：DCF 模型的看法</h2>
</div><p>While the P/S of 3.4x looks expensive against healthcare peers, our DCF model points in a different direction. It indicates a fair value of S$0.11 per share versus the current S$0.06, suggesting that Thomson Medical Group is trading at a sizable discount. Which signal do you trust more?</p>
<div class="lb-trans"><p>虽然 3.4 倍的市销率在医疗同行中显得昂贵，但我们的 DCF 模型指向了不同的方向。它表明每股合理价值为 0.11 新元，而当前为 0.06 新元，这表明 Thomson Medical Group 的交易价格存在较大折扣。你更信任哪个信号？</p>
</div><p>Look into how the SWS DCF model arrives at its fair value.</p>
<div class="lb-trans"><p>了解 SWS DCF 模型如何得出其合理价值。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e690d03f-7cdf-477b-86cf-107b2708eedc/chart/dcf" alt="" original-src="https://images.simplywall.st/company/e690d03f-7cdf-477b-86cf-107b2708eedc/chart/dcf"/></p>
<p>A50 Discounted Cash Flow as at Feb 2026</p>
<div class="lb-trans"><p>截至 2026 年 2 月的 A50 折现现金流</p>
</div><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Thomson Medical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 221 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.</p>
<div class="lb-trans"><p>Simply Wall St 每天对全球每只股票进行折现现金流（DCF）分析（例如查看 Thomson Medical Group）。我们展示了完整的计算过程。你可以在你的观察列表或投资组合中跟踪结果，并在变化时收到提醒，或者使用我们的股票筛选器发现 221 只高质量的被低估股票。如果你保存了筛选器，我们甚至会在新公司匹配时提醒你——这样你就不会错过潜在机会。</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><p>If this mix of signals leaves you slightly conflicted, that is a healthy place to start. It is worth moving quickly to test your own view against the numbers and context behind 2 key rewards and 1 important warning sign.</p>
<div class="lb-trans"><p>如果这些信号的组合让你感到有些矛盾，那是一个健康的开始。值得迅速行动，以便将自己的观点与 2 个关键回报和 1 个重要警告信号背后的数字和背景进行对比。</p>
</div><h2>Looking for more investment ideas?</h2>
<div class="lb-trans"><h2>寻找更多投资想法？</h2>
</div><p>If Thomson Medical Group has sharpened your focus, do not stop here. Use this momentum to compare other opportunities and pressure test your portfolio decisions.</p>
<div class="lb-trans"><p>如果 Thomson Medical Group 让你更加关注，不要止步于此。利用这一势头比较其他机会，并对你的投资组合决策进行压力测试。</p>
</div><ul>
<li>Target potential value candidates by scanning our list of 221 high quality undervalued stocks that pair solid fundamentals with more modest pricing.</li>
<li>Strengthen the quality of your holdings by checking our solid balance sheet and fundamentals stocks screener (369 results) and see which companies back their stories with robust finances.</li>
<li>Add a potential income angle by reviewing our 438 dividend fortresses so you do not miss companies offering higher yields with staying power.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过扫描我们 221 只高质量被低估股票的列表，寻找潜在的价值候选者，这些股票结合了稳健的基本面和更温和的定价。</li>
<li>通过检查我们的稳健资产负债表和基本面股票筛选器（369 个结果），增强你持有股票的质量，看看哪些公司用强健的财务支持他们的故事。</li>
<li>通过审查我们的 438 只股息堡垒，增加潜在的收入角度，以免错过提供更高收益且具有持久力的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值复杂，但我们在这里简化它。</h3>
</div><p>Discover if Thomson Medical Group might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通过我们的详细分析，发现 Thomson Medical Group 是否可能被低估或高估，分析内容包括 <strong>合理价值估算、潜在风险、股息、内部交易及其财务状况。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>获取免费分析</p>
</div>

在亏损缩小和半年销售额增加后，杰俐医疗集团（SGX:A50）的估值检查